CordenPharma signs billion dollar agreement to manufacture new peptide

[Photo by CordenPharma] Commercial Peptide Manufacturing at CordenPharma Colorado (CO; USA).

CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities. 

Depending on the total production volume at the end of the contract, the agreement is expected to reach a value of US$ 1 billion. It will enable the launch of a new commercial peptide, but the details are still being kept under wraps with respect to the confidentiality of the customer.   

Dr Michael Quirmbach, CEO & President of CordenPharma, commented: 

“We are very excited about the trust our customer has placed in CordenPharma, and are pleased to continue supporting the commercial manufacturing of this innovative peptide at our CordenPharma Colorado site, which is perfectly equipped for producing these types of complex molecules. As part of our commitment, we plan to further expand both our large and medium-scale peptide manufacturing capacity at our Colorado and Frankfurt sites, making CordenPharma the leading peptide manufacturing CDMO with full drug product integration, possible via our aseptic fill and finish capabilities in CordenPharma Caponago.”

Separate to this agreement, CordenPharma – as hinted at in their recent interview from CPHI Frankfurt 2022 – are investing in expanding their capabilities and technologies across their portfolio, focusing mainly on peptides, lipids, and injectables. They plan to invest nearly €200 million in 2023 to further the development of their high-value products.